REGULATORY

• FPMAJ Prods Drastic Review of Fiscal Framework before Honebuto 2025
  March 25, 2025

• Difficult to “Visualize” Distribution, Production Costs in NHI Prices: Minister
  March 25, 2025

• MHLW Panel Discusses Ways to Promote Clinical Trials
  March 24, 2025

• PMDA Issues Guidance for Pediatric Drug Development
  March 24, 2025

• US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
  March 19, 2025

• MHLW to Investigate Pharmaceutical Ad Regulations in US, Europe
  March 18, 2025

• MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
  March 17, 2025

• PMDA Reviewing Safety Risks of Paxlovid/Xtandi Concurrent Use
  March 17, 2025

• MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
  March 14, 2025

• JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
  March 14, 2025

• Chuikyo to Discuss Potential Pricing Steps to Deal with Higher Costs of Japan-Made APIs
  March 13, 2025

• MHLW to Extend NIP Period for MR Vaccines by 2 Years amid Shortage
  March 13, 2025

• Chuikyo Rep Calls for Proper Use of Zepbound, Frets Expansion of Obesity Market
  March 13, 2025

• Imdelltra, Balversa, 2 More New Drugs Skip March Listing
  March 13, 2025

• Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
  March 13, 2025

• MHLW to “Listen to Industry Opinions” in Policymaking around CEA: Minister
  March 13, 2025

• CellCept Now Covered for Nephrotic Syndrome: MHLW
  March 13, 2025

• Litfulo’s Price to Be Trimmed 3.8% in June after CEA
  March 13, 2025

• Re-Priced Unprofitable Products Subject to Unit Price-Based Trades for 2 Years: MHLW
  March 12, 2025

• Trerief and Nobelzin Newly Added to Elective Care Scheme; Allegra, Takepron Excluded
  March 12, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 33
• 34
• 35
• 36
• 37
• 38
• 39
• 40
• 41
• …
• Next ›
• 最終 »